June 11, 2012

Sanofi Submits Application for Regulatory Approval for Lyxumia® (lixisenatide) for the Treatment of Type 2 Diabetes in Japan

 

Sanofi Submits Application for Regulatory Approval for Lyxumia® (lixisenatide) for the Treatment of Type 2 Diabetes in Japan

Paris, France – June 11, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the marketing authorization application for Lyxumia® (lixisenatide), an investigational once-daily GLP-1 receptor agonist has been submitted for review to the Ministry of Health, Labour and Welfare in Japan.